tiprankstipranks
Trending News
More News >
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
US Market

Eupraxia Pharmaceuticals (EPRX) Income Statement

Compare
30 Followers

Eupraxia Pharmaceuticals Income Statement

Last quarter (Q4 2025), Eupraxia Pharmaceuticals's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q4, Eupraxia Pharmaceuticals's net income was C$-23.30M. See Eupraxia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Mar 24Dec 22Dec 21
Total Revenue
C$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross Profit
C$ -332.16KC$ -235.25KC$ -209.91KC$ -193.27KC$ -111.53K
Operating Expenses
C$ 53.37MC$ 36.76MC$ 37.92MC$ 23.20MC$ 18.68M
Depreciation and Amortization
C$ 332.16KC$ 235.25KC$ 209.91KC$ 193.27KC$ 111.53K
EBITDA
C$ -53.37MC$ -33.72MC$ -37.40MC$ -22.14MC$ -21.96M
Operating Income
C$ -53.70MC$ -36.99MC$ -36.90MC$ -22.63MC$ -20.87M
Other Income/Expenses
C$ -213.12KC$ 1.73MC$ -2.29MC$ -64.07KC$ -5.46M
Pretax Income
C$ -53.92MC$ -35.27MC$ -39.18MC$ -23.92MC$ -23.37M
Net Income
C$ -53.90MC$ -34.94MC$ -37.39MC$ -23.26MC$ -22.99M
Per Share Metrics
Basic EPS
C$ -1.44C$ -1.03C$ -1.58C$ -1.21C$ -1.61
Diluted EPS
C$ -1.44C$ -1.03C$ -1.58C$ -1.21C$ -1.61
Weighted Average Shares Outstanding
39.96M 33.93M 24.15M 19.29M 14.24M
Weighted Average Shares Outstanding (Diluted)
39.96M 33.93M 24.15M 19.29M 14.24M
Currency in CAD

Eupraxia Pharmaceuticals Earnings and Revenue History